In light of recent findings, would you consider prescribing dutasteride to men with low-risk prostate cancer to reduce their risk of PCa progression?

Share this article:

A randomized, double-blind study published recently in The Lancet showed that men on active surveillance for low-risk prostate cancer (PCa) who received the 5α-reductase inhibitor dutasteride for three years had a significant 38% decreased risk of PCa progression compared with men who took placebo. The investigators concluded that their findings “show that dutasteride could be a beneficial adjunct to active surveillance for men with low-risk prostate cancer, delaying their time to pathological progression and initiation of primary therapy.”

Renal & Urology News would like to ask its urologist readers the following question.


Leave a comment below to explain your choice.
Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

What do you think of the penalties assessed against drug companies accused ...

Pharmaceutical companies have paid billions of dollars to settle federal allegations of fraud and other wrongdoing in recent years.

Do doctors have a moral duty to serve as expert witnesses in ...

Thousands of medical malpractice suits are filed in courts across the U.S. each year.

Do you have any patients who acquired a kidney transplant abroad?

More than 90,000 kidney transplant candidates are on transplant waiting lists in the U.S.